Pacific Biosciences of California, Inc. (PACB) Total Assets by Year
Pacific Biosciences of California, Inc. closed fiscal year 2025 with $784.1M in total assets, $778.7M in total liabilities and $5.3M in shareholder equity. This represents a decrease of 37.8% from the prior fiscal year. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Pacific Biosciences of California, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
PACB Balance Sheet by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $784.1M-37.8% | $1.3B-27.8% | $1.7B-1.2% | $1.8B-12.0% | $2.0B+384.8% | $414.0M+179.7% | $148.0M-13.1% | $170.3M+18.2% | $144.1M+4.5% | $137.9M+5.2% | $131.1M+5.4% | $124.4M-8.7% | $136.2M+5.0% | $129.7M-40.6% | $218.3M |
| Total Liabilities | $778.7M+3.3% | $753.9M-27.8% | $1.0B-13.2% | $1.2B-1.0% | $1.2B+1449.2% | $78.5M-15.7% | $93.1M+65.6% | $56.2M-3.0% | $58.0M+9.0% | $53.2M-7.6% | $57.6M-17.1% | $69.4M+3.6% | $67.0M+230.1% | $20.3M-24.4% | $26.9M |
| Total Equity | $5.3M-98.9% | $506.6M-27.8% | $701.3M+24.6% | $562.9M-28.8% | $791.0M+135.8% | $335.5M+510.9% | $54.9M-51.9% | $114.1M+32.5% | $86.1M+1.7% | $84.7M+15.1% | $73.5M+33.8% | $54.9M-20.6% | $69.2M-36.8% | $109.4M-42.9% | $191.5M |
PACB Balance Sheet by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $751.9M-8.9% | $782.4M-9.1% | $784.1M-37.8% | $803.2M-44.6% | $825.5M-45.3% | $860.8M-48.5% | $1.3B-27.8% | $1.5B-23.6% | $1.5B-18.3% | $1.7B-11.9% | $1.7B-1.2% | $1.9B+4.4% |
| Total Liabilities | $785.1M+2.8% | $780.0M+1.4% | $778.7M+3.3% | $767.1M-23.1% | $764.0M-24.9% | $769.2M-24.7% | $753.9M-27.8% | $996.9M-12.1% | $1.0B-15.7% | $1.0B-15.2% | $1.0B-13.2% | $1.1B-4.8% |
| Total Equity | -$33.2M-154.0% | $2.4M-97.4% | $5.3M-98.9% | $36.1M-92.0% | $61.5M-87.5% | $91.6M-85.9% | $506.6M-27.8% | $453.1M-40.7% | $492.7M-23.3% | $649.0M-6.2% | $701.3M+24.6% | $763.7M+21.9% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Pacific Biosciences of California, Inc. financials
Frequently Asked Questions
What was Pacific Biosciences of California, Inc.'s total assets in fiscal year 2025?
Pacific Biosciences of California, Inc. closed fiscal year 2025 with $784.1M in total assets, $778.7M in total liabilities and $5.3M in shareholder equity.
How fast is Pacific Biosciences of California, Inc.'s total assets growing?
Pacific Biosciences of California, Inc. (PACB) total assets fell by 37.8% year over year, from $1.3B to $784.1M in fiscal year 2025.
How has Pacific Biosciences of California, Inc.'s total assets changed over the years?
Across the 15 fiscal years this page covers, Pacific Biosciences of California, Inc. (PACB) total assets went from $218.3M in fiscal year 2011 to $784.1M in fiscal year 2025.
What was Pacific Biosciences of California, Inc.'s total assets in the most recent quarter?
Pacific Biosciences of California, Inc. (PACB) reported $751.9M in total assets in Q2 2026. This represents a decrease of 8.9% from the same quarter a year earlier.
What does total assets mean on a financial statement?
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Pacific Biosciences of California, Inc. (PACB) reported on that line in every period on record.